Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar


In a recent development with the ongoing complex litigation involving Janssen Biotech's arthritis biologic medicine Remicade and Celltrion's biosimilar, [1] Celltrion's partner Pfizer has filed a suit against Janssen's parent company Johnson & Johnson in the Eastern District of Pennsylvania alleging that through anticompetitive pricing and exclusionary contracts with insurers and hospitals, J&J sought to preserve a monopoly over its sale of Remicade. [2] Pfizer alleges that these practices by J&J prevent it from entering into the market with its own biosimilar version of Remicade.



from Biotech News